Mithramycin A suppresses expression of the human melanoma-associated gene ABCB8

Iwona Sachrajda1, Marcin Ratajewski

  • 1Laboratory of Transcriptional Regulation, Institute of Medical Biology, Polish Academy of Sciences, Lodowa 106, 93-232 Lodz, Poland.

Insights

Researchers identified the Sp1 transcription factor as a key regulator of the ABCB8 gene. Inhibiting Sp1 reduced ABCB8 expression and increased melanoma cell sensitivity to chemotherapy.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Genetics

Background:

  • The function of the ABCB8 gene in human cells remains largely unknown.
  • ABCB8 is potentially implicated in multidrug resistance observed in certain cancers, such as melanoma.

Purpose of the Study:

  • To elucidate the primary mechanism of transcriptional regulation for the ABCB8 gene.
  • To investigate the role of transcription factor Sp1 in controlling ABCB8 gene expression.

Main Methods:

  • Electrophoretic Mobility Shift Assay (EMSA) and Chromatin Immunoprecipitation (ChIP) assays were employed.
  • Luciferase reporter gene assays were used to assess promoter activity.
  • Mithramycin A, an Sp1 inhibitor, was utilized to study gene expression changes.

Main Results:

  • The transcription factor Sp1 was confirmed to bind to the core promoter region of the ABCB8 gene.
  • Sp1 consensus elements were found to be essential for ABCB8 promoter activity.
  • Mithramycin A treatment led to a dose-dependent decrease in ABCB8 and other ABC gene expression.
  • The inhibition of Sp1 binding sensitized melanoma cells to doxorubicin, a chemotherapy drug.

Conclusions:

  • Sp1 is a critical transcriptional regulator of the ABCB8 gene.
  • Targeting Sp1 may offer a therapeutic strategy for specific melanoma patient subsets.
  • Understanding ABCB8 regulation could enhance multidrug resistance treatments in cancer.